115 related articles for article (PubMed ID: 1451241)
1. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect.
Blankenhorn DH; Selzer RH; Mack WJ; Crawford DW; Pogoda J; Lee PL; Shircore AM; Azen SP
Circulation; 1992 Dec; 86(6):1701-9. PubMed ID: 1451241
[TBL] [Abstract][Full Text] [Related]
2. Serial quantitative coronary angiography and coronary events.
Mack WJ; Xiang M; Selzer RH; Hodis HN
Am Heart J; 2000 Jun; 139(6):993-9. PubMed ID: 10827379
[TBL] [Abstract][Full Text] [Related]
3. Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials.
Mack WJ; Selzer RH; Pogoda JM; Lee PL; Shircore AM; Azen SP; Blankenhorn DH
Arterioscler Thromb; 1992 Mar; 12(3):348-56. PubMed ID: 1547194
[TBL] [Abstract][Full Text] [Related]
4. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.
Azen SP; Mack WJ; Cashin-Hemphill L; LaBree L; Shircore AM; Selzer RH; Blankenhorn DH; Hodis HN
Circulation; 1996 Jan; 93(1):34-41. PubMed ID: 8616937
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.
Blankenhorn DH; Nessim SA; Johnson RL; Sanmarco ME; Azen SP; Cashin-Hemphill L
JAMA; 1987 Jun; 257(23):3233-40. PubMed ID: 3295315
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of two lipid-lowering treatments on quantitative coronary angiographic endpoints.
Mack WJ; Xiang M; Shircore AM; Selzer RH; Hodis HN; Azen SP
Cardiovasc Drugs Ther; 2000 Aug; 14(4):411-8. PubMed ID: 10999648
[TBL] [Abstract][Full Text] [Related]
7. Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography.
Mack WJ; LaBree L; Liu C; Selzer RH; Hodis HN
Atherosclerosis; 2000 Jun; 150(2):371-9. PubMed ID: 10856529
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.
Cashin-Hemphill L; Mack WJ; Pogoda JM; Sanmarco ME; Azen SP; Blankenhorn DH
JAMA; 1990 Dec; 264(23):3013-7. PubMed ID: 2243429
[TBL] [Abstract][Full Text] [Related]
9. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
[TBL] [Abstract][Full Text] [Related]
10. Effects of colestipol-niacin therapy on human femoral atherosclerosis.
Blankenhorn DH; Azen SP; Crawford DW; Nessim SA; Sanmarco ME; Selzer RH; Shircore AM; Wickham EC
Circulation; 1991 Feb; 83(2):438-47. PubMed ID: 1991366
[TBL] [Abstract][Full Text] [Related]
11. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis.
Hodis HN; Mack WJ; LaBree L; Cashin-Hemphill L; Sevanian A; Johnson R; Azen SP
JAMA; 1995 Jun; 273(23):1849-54. PubMed ID: 7776501
[TBL] [Abstract][Full Text] [Related]
12. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study.
Hodis HN
J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S25-31. PubMed ID: 8907211
[TBL] [Abstract][Full Text] [Related]
13. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors.
Blankenhorn DH; Alaupovic P; Wickham E; Chin HP; Azen SP
Circulation; 1990 Feb; 81(2):470-6. PubMed ID: 2404631
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound.
Blankenhorn DH; Selzer RH; Crawford DW; Barth JD; Liu CR; Liu CH; Mack WJ; Alaupovic P
Circulation; 1993 Jul; 88(1):20-8. PubMed ID: 8319334
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of human panelists in assessing coronary atherosclerosis.
Azen SP; Cashin-Hemphill L; Pogoda J; Mack WJ; Sanmarco ME; Wickham E; Blankenhorn DH
Arterioscler Thromb; 1991; 11(2):385-94. PubMed ID: 1998656
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
Zambon A; Hokanson JE; Brown BG; Brunzell JD
Circulation; 1999 Apr; 99(15):1959-64. PubMed ID: 10208998
[TBL] [Abstract][Full Text] [Related]
17. Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression.
Berry C; L'Allier PL; Grégoire J; Lespérance J; Levesque S; Ibrahim R; Tardif JC
Circulation; 2007 Apr; 115(14):1851-7. PubMed ID: 17389269
[TBL] [Abstract][Full Text] [Related]
18. A comparison of quantitative computerized and human panel coronary endpoint measures: implications for the design of angiographic trials.
Mack WJ; Azen SP; Dunn M; Hodis HN
Control Clin Trials; 1997 Apr; 18(2):168-79. PubMed ID: 9129860
[TBL] [Abstract][Full Text] [Related]
19. Colestipol-niacin therapy and coronary atherosclerosis.
JAMA; 1987 Nov; 258(19):2694-6. PubMed ID: 3669238
[No Abstract] [Full Text] [Related]
20. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).
Blankenhorn DH; Azen SP; Kramsch DM; Mack WJ; Cashin-Hemphill L; Hodis HN; DeBoer LW; Mahrer PR; Masteller MJ; Vailas LI; Alaupovic P; Hirsch LJ;
Ann Intern Med; 1993 Nov; 119(10):969-76. PubMed ID: 8214993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
